Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants

Journal of Clinical Oncology

Volumn 29, Issue 23, 2011, Pages 3194-3200

  Trotman, Judith ^a   Fournier, Marion ^e   Lamy, Thierry ^f   Seymour, John Francis ^c   Sonet, Anne ^o   Janikova, Andrea ^q   Shpilberg, Ofer ^r,s   Gyan, Emmanuel ^g   Tilly, Hervé ^h   Estell, Jane ^a   Forsyth, Cecily ^d   Decaudin, Didier ⁱ   Fabiani, Bettina ^j   Gabarre, Jean ^k   Salles, Bruno ^m   Van Den Neste, Eric ^p   Canioni, Danielle ^l   Garin, Etienne ^f   Fulham, Michael ^b   Borght, Thierry Vander ^o   Salles, Gilles ⁿ   more..

^a Department of Microbiology and Infectious Diseases   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Wyong Hospital   (Australia)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

^h UNIVERSITÉ DE ROUEN   (France)

ⁱ INSTITUT CURIE   (France)

^j HÔPITAL SAINT ANTOINE   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

^m CENTRE HOSPITALIER   (France)

ⁿ UNIVERSITÉ LYON 1   (France)

^o UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^p UCL Saint Luc   (Belgium)

^q UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^r RABIN MEDICAL CENTER   (Israel)

^s TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 80051821494     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.0736     Document Type: Article

References (29)

1. Solal-Céligny P., Roy P., Colombat P., et al: Follicular Lymphoma International Prognostic Index. Blood 104:1258-1265, 2004 (Pubitemid 39166497)
2. Buske C., Hoster E., Dreyling M., et al: The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108:1504-1508, 2006 (Pubitemid 44321768)
3. Federico M., Bellei M., Marcheselli L., et al: Follicular Lymphoma International Prognostic Index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 27:4555-4562, 2009
4. Relander T., Johnson N.A., Farinha P., et al: Prognostic factors in follicular lymphoma. J Clin Oncol 28:2902-2913, 2010
5. Cheson B.D., Horning S.J., Coiffier B., et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999 (Pubitemid 29162950)
6. Buckstein R., Pennell N., Berinstein N.L.: What is remission in follicular lymphoma and what is its relevance? Best Pract Res Clin Haematol 18:27-56, 2005 (Pubitemid 40197864)
7. Bachy E., Brice P., Delarue R., et al: Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: Effect of response quality on survival - A study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 28:822-829, 2010
8. Juweid M.E., Stroobants S., Hoekstra O.S., et al: Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578, 2007 (Pubitemid 350002965)
9. Cheson B.D., Pfistner B., Juweid M.E., et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
10. Shankar L.K., Hoffman J.M., Bacharach S., et al: Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47:1059-1066, 2006 (Pubitemid 46939960)
11. Tang B., Malysz J., Douglas-Nikitin V., et al: Correlating metabolic activity with cellular proliferation in follicular lymphomas. Mol Imaging Biol 11:296-302, 2009
12. Allen-Auerbach M., De Vos S., Czernin J.: The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am 46:199-211, 2008 (Pubitemid 351932039)
13. Le Dortz L., De Guibert S., Bayat S., et al: Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 37:2307-2314, 2010
14. Bishu S., Quigley J.M., Bishu S.R., et al: Predictive value and diagnostic accuracy of F-18-fluoro-deoxyglucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 48:1548-1555, 2007 (Pubitemid 47272805)
15. Janikova A., Bolcak K., Pavlik T., et al: Value of [18F] fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma? Clin Lymphoma Myeloma 8:287-293, 2008
16. Zinzani P.L., Musuraca G., Alinari L., et al: Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 7:291-295, 2007 (Pubitemid 46408194)
17. Jacobs S.A., Swerdlow S.H., Kant J., et al: Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 14:7088-7094, 2008
18. Lopci E., Santi I., Derenzini E., et al: FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: Multicentric study. Ann Oncol 21:1877-1883, 2010
19. Swenson W.T., Wooldridge J.E., Lynch C.F., et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005 (Pubitemid 46224008)
20. Liu Q., Fayad L., Cabanillas F., et al: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24:1582-1589, 2006 (Pubitemid 46638782)
21. Salles G., Seymour J.F., Offner F., et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
22. Weiler-Sagie M., Bushelev O., Epelbaum R., et al: (18)F-FDG avidity in lymphoma readdressed: A study of 766 patients. J Nucl Med 51:25-30, 2010
23. Wirth A., Foo M., Seymour J.F., et al: Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 71:213-219, 2008
24. Wöhre S., Jaeger U., Kletter K., et al: 18F-fluorodeoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 17:780-784, 2006
25. Blum R.H., Seymour J.F., Wirth A., et al: Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 4:43-49, 2003 (Pubitemid 36826876)
26. Karam M., Novak L., Cyriac J., et al: Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107:175-183, 2006 (Pubitemid 43939045)
27. Elstrom R., Guan L., Baker G., et al: Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875-3876, 2003 (Pubitemid 36857861)
28. Jerusalem G., Beguin Y., Najjar F., et al: Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 12:825-830, 2001 (Pubitemid 32655093)
29. Meignan M., Gallamini A., Meignan M., et al: Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 50:1257-1260, 2009